Why Is MEDICAL PPTYS TR INC REIT (MPT) Stock Moving Today?

MPT shares fell 14.96% to $2.08 on October 30, 2026. The primary driver was a downgrade by RBC Capital Markets following third-quarter results that missed estimates.

What Happened

RBC Capital Markets cut its recommendation on Medical Properties Trust to Underperform and lowered its price target to $2.00. The decision followed the company’s Q3 2026 earnings release, where normalized FFO of $0.11 missed the $0.13 estimate, and sales of $250.140 million fell short of the $257.977 million consensus.

During the earnings call, management highlighted a balance sheet restructuring and operator stabilization. The company reported collecting more than $750 million in cash rental revenue year-to-date, which annualizes above the $1 billion target. Management also noted a $2.4 billion refinancing advance and projected 2027 portfolio cash rents above $1 billion. However, uncertainty persists regarding HSA rent, with the company resetting Priory rent by approximately 18%.

What The Data Shows

The stock opened at $2.42, a 1.0% gap down from the prior close of $2.44. The session high was $2.44 at 7:20 AM ET, while the session low reached $2.07 at 12:00 PM ET. Volume totaled 15.5 million shares, which is 1.6 times the three-month daily average.

Fundamentals show a market cap of $1.6 billion and a beta of 1.49. The company remains unprofitable with a trailing twelve-month EPS of -0.05 and a net margin of -2.7%. Revenue grew 12.1% over the same period. The dividend yield stands at 13.09%. The 52-week range is $2.35 to $6.47, and the stock printed 19 fresh 52-week lows on October 30, 2026.

Unusual options activity included one notable print with $352,000 in put premium and no call premium. Recent insider filings show one buy totaling $10,000 by SVP and Controller Kevin Hanna on August 20, 2026. Congressional disclosures indicate three sells by Donald J. Trump in the last 90 days, with the most recent filing on October 8, 2026.

What To Watch

Investors will monitor coverage breadth and potential further analyst reactions to the Q3 miss. The next scheduled earnings date is not provided in the current data.